Author:
Pareyson Davide,Reilly Mary M,Schenone Angelo,Fabrizi Gian Maria,Cavallaro Tiziana,Santoro Lucio,Vita Giuseppe,Quattrone Aldo,Padua Luca,Gemignani Franco,Visioli Francesco,Laurà Matilde,Radice Davide,Calabrese Daniela,Hughes Richard AC,Solari Alessandra
Funder
Telethon-UILDM
AIFA (Italian Medicines Agency
the Muscular Dystrophy Campaign in the UK
Reference24 articles.
1. Diagnosis, natural history, and management of Charcot–Marie–Tooth disease;Pareyson;Lancet Neurol,2009
2. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease;Passage;Nat Med,2004
3. Ascorbic acid inhibits PMP22 expression by reducing cAMP levels;Kaya;Neuromuscul Disord,2007
4. Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial;Verhamme;BMC Med,2009
5. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial;Burns;Lancet Neurol,2009
Cited by
217 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献